EFFECT OF IBANDRONATE ON RISKS FOR VERTEBRAL AND NONVERTEBRAL FRACTURES IN POSTMENOPAUSALOSTEOPOROSIS (A REVIEW OF CLINICAL TRIALS)

EFFECT OF IBANDRONATE ON RISKS FOR VERTEBRAL AND NONVERTEBRAL FRACTURES IN POSTMENOPAUSALOSTEOPOROSIS (A REVIEW OF CLINICAL TRIALS)

Show other versions (1)

The paper presents data of a large number of clinical trials meeting the principles of evidence-based medicines, which have dealt with the evaluation of the efficacy of ibandronate in postmenopausal osteoporosis (OP). The administration of its registered formulations (150 mg weekly oral and 3 mg qua...

Full description

Bibliographic Details
Main Author: Evgeni Germanovich Zotkin
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2010-06-01
Series:Современная ревматология
Subjects:
postmenopausal osteoporosis
ibandronate
Online Access:https://mrj.ima-press.net/mrj/article/view/286
id doaj-a6e1acaa66af46c689b121d7bc8a2388
record_format Article
spelling doaj-a6e1acaa66af46c689b121d7bc8a23882021-07-29T09:00:06ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2010-06-0142424610.14412/1996-7012-2010-6011591EFFECT OF IBANDRONATE ON RISKS FOR VERTEBRAL AND NONVERTEBRAL FRACTURES IN POSTMENOPAUSALOSTEOPOROSIS (A REVIEW OF CLINICAL TRIALS)Evgeni Germanovich ZotkinThe paper presents data of a large number of clinical trials meeting the principles of evidence-based medicines, which have dealt with the evaluation of the efficacy of ibandronate in postmenopausal osteoporosis (OP). The administration of its registered formulations (150 mg weekly oral and 3 mg quarterly intravenous) is shown to reduce the risk of both vertebral and nonvertebral fractures, including proximal femoral fractures. It is emphasized that adequate patient adherence to antiosteopotic therapy to achieve an acceptable annual cumulative dose is one of the most important goals of effective therapy for OPhttps://mrj.ima-press.net/mrj/article/view/286postmenopausal osteoporosisibandronate
collection DOAJ
language Russian
format Article
sources DOAJ
author Evgeni Germanovich Zotkin
spellingShingle Evgeni Germanovich Zotkin
EFFECT OF IBANDRONATE ON RISKS FOR VERTEBRAL AND NONVERTEBRAL FRACTURES IN POSTMENOPAUSALOSTEOPOROSIS (A REVIEW OF CLINICAL TRIALS)
Современная ревматология
postmenopausal osteoporosis
ibandronate
author_facet Evgeni Germanovich Zotkin
author_sort Evgeni Germanovich Zotkin
title EFFECT OF IBANDRONATE ON RISKS FOR VERTEBRAL AND NONVERTEBRAL FRACTURES IN POSTMENOPAUSALOSTEOPOROSIS (A REVIEW OF CLINICAL TRIALS)
title_short EFFECT OF IBANDRONATE ON RISKS FOR VERTEBRAL AND NONVERTEBRAL FRACTURES IN POSTMENOPAUSALOSTEOPOROSIS (A REVIEW OF CLINICAL TRIALS)
title_full EFFECT OF IBANDRONATE ON RISKS FOR VERTEBRAL AND NONVERTEBRAL FRACTURES IN POSTMENOPAUSALOSTEOPOROSIS (A REVIEW OF CLINICAL TRIALS)
title_fullStr EFFECT OF IBANDRONATE ON RISKS FOR VERTEBRAL AND NONVERTEBRAL FRACTURES IN POSTMENOPAUSALOSTEOPOROSIS (A REVIEW OF CLINICAL TRIALS)
title_full_unstemmed EFFECT OF IBANDRONATE ON RISKS FOR VERTEBRAL AND NONVERTEBRAL FRACTURES IN POSTMENOPAUSALOSTEOPOROSIS (A REVIEW OF CLINICAL TRIALS)
title_sort effect of ibandronate on risks for vertebral and nonvertebral fractures in postmenopausalosteoporosis (a review of clinical trials)
publisher IMA-PRESS LLC
series Современная ревматология
issn 1996-7012
2310-158X
publishDate 2010-06-01
description The paper presents data of a large number of clinical trials meeting the principles of evidence-based medicines, which have dealt with the evaluation of the efficacy of ibandronate in postmenopausal osteoporosis (OP). The administration of its registered formulations (150 mg weekly oral and 3 mg quarterly intravenous) is shown to reduce the risk of both vertebral and nonvertebral fractures, including proximal femoral fractures. It is emphasized that adequate patient adherence to antiosteopotic therapy to achieve an acceptable annual cumulative dose is one of the most important goals of effective therapy for OP
topic postmenopausal osteoporosis
ibandronate
url https://mrj.ima-press.net/mrj/article/view/286
work_keys_str_mv AT evgenigermanovichzotkin effectofibandronateonrisksforvertebralandnonvertebralfracturesinpostmenopausalosteoporosisareviewofclinicaltrials
_version_ 1721250431268552704

Similar Items